Why ImmunoGen (IMGN) Stock Is Down Today

NEW YORK (TheStreet) -- ImmunoGen (IMGN) stock is tumbling on Friday after the biotechnology company saw third-quarter losses gap wider than expected and as revenue fell short of analysts' estimates. 

By midday, shares had dropped -7.2% to $12.80.

SELL NOW: If you own any of the 900 stocks that TheStreet Quant Ratings has identified as a 'Sell'...you could potentially lose EVERYTHING in the next 6-12 months. Learn more. 

Over the three months to March, Waltham, Mass.-based ImmunoGen reported a net loss of 44 cents a share compared to losses of 2 cents a share in the year-ago quarter. Analysts surveyed by Thomson Reuters had forecast a net loss of 27 cents a share. 

Revenue tumbled to $6.88 million from $25 million a year earlier, missing estimates of $13.28 million.

Must read: Warren Buffett's 10 Favorite Growth Stocks

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Amazon Falls, Obamacare Repeal Fails - 5 Things You Must Know Before the Market Opens

7 Stocks Under $10 Making Big Up Moves

Strong On High Relative Volume: Immunogen (IMGN)